MedTrace Logo

MCT8 Deficiency Caregiver Study

NCT06060197 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 21

Last updated 2024-04-25

No results posted yet for this study

Summary

Caregivers face many responsibilities outside of their role as a friend or parent, which can lead to emotional, financial, social, and professional challenges. To better understand the impact of MCT8 deficiency on caregivers, Egetis Therapeutics are conducting an online survey for adult caregivers of persons living with the MCT8 deficiency.

Conditions

  • Monocarboxylate Transporter 8 (MCT8) Deficiency
  • Allan-Herndon-Dudley Syndrome

Sponsors & Collaborators

  • Vitaccess Ltd

    collaborator INDUSTRY

  • Rare Thyroid Therapeutics International AB

    lead INDUSTRY

Principal Investigators

  • Mark Larkin, PhD · Vitaccess Limited

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-08-23
Primary Completion
2024-04-12
Completion
2024-04-12

Countries

  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06060197 on ClinicalTrials.gov